Assessing reproducibility of diffusion-weighted magnetic resonance imaging studies in a murine model of HER2+ breast cancer

Magnetic Resonance Imaging

Volumn 32, Issue 3, 2014, Pages 245-249

  Whisenant, Jennifer G ^a   Ayers, Gregory D ^a   Loveless, Mary E ^a   Barnes, Stephanie L ^a   Colvin, Daniel C ^a   Yankeelov, Thomas E ^a,b,c,d  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Apparent diffusion coefficient; Diffusion weighted MRI; Mouse; Reproducibility

Indexed keywords

APPARENT DIFFUSION COEFFICIENT; DIFFUSION-WEIGHTED MRI; MOUSE; REPRODUCIBILITY;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DIFFUSION MAGNETIC RESONANCE IMAGING; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MICE; MICE, NUDE; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84894252973     PISSN: 0730725X     EISSN: 18735894     Source Type: Journal    
DOI: 10.1016/j.mri.2013.10.013     Document Type: Article

References (30)

1. Wahl R.L., Jacene H., Kasamon Y., Lodge M.A. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009, 50(Suppl 1):122S-150S.
2. Guarneri V., Barbieri E., Dieci M.V., Piacentini F., Conte P. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. Cancer Treat Rev 2010, 36(Suppl 3):S62-S66.
3. Jackson J.R., Patrick D.R., Dar M.M., Huang P.S. Targeted anti-mitotic therapies: can we improve on tubulin agents?. Nat Rev Cancer 2007, 7(2):107-117.
4. Galons J.P., Altbach M.I., Paine-Murrieta G.D., Taylor C.W., Gillies R.J. Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia 1999, 1(2):113-117.
5. Jensen L.R., Garzon B., Heldahl M.G., Bathen T.F., Lundgren S., Gribbestad I.S. Diffusion-weighted and dynamic contrast-enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients. J Magn Reson Imaging 2011, 34(5):1099-1109.
6. Jordan B.F., Runquist M., Raghunand N., Baker A., Williams R., Kirkpatrick L., et al. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia 2005, 7(5):475-485.
7. Karroum O., Mignion L., Kengen J., Karmani L., Leveque P., Danhier P., et al. Multimodal imaging of tumor response to sorafenib combined with radiation therapy: comparison between diffusion-weighted MRI, choline spectroscopy and (18) F-FLT PET imaging. Contrast Media Mol Imaging 2013, 8(3):274-280.
8. Anderson A.W., Xie J., Pizzonia J., Bronen R.A., Spencer D.D., Gore J.C. Effects of cell volume fraction changes on apparent diffusion in human cells. Magn Reson Imaging 2000, 18(6):689-695.
9. Aliu S.O., Wilmes L.J., Moasser M.M., Hann B.C., Li K.L., Wang D., et al. MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model. J Magn Reson Imaging 2009, 29(5):1071-1079.
10. Larocque M.P., Syme A., Allalunis-Turner J., Fallone B.G. ADC response to radiation therapy correlates with induced changes in radiosensitivity. Med Phys 2010, 37(7):3855-3861.
11. Lee S.C., Poptani H., Pickup S., Jenkins W.T., Kim S., Koch C.J., et al. Early detection of radiation therapy response in non-Hodgkin's lymphoma xenografts by in vivo 1H magnetic resonance spectroscopy and imaging. NMR Biomed 2010, 23(6):624-632.
12. Loveless M.E., Lawson D., Collins M., Nadella M.V., Reimer C., Huszar D., et al. Comparisons of the efficacy of a Jak1/2 inhibitor (AZD1480) with a VEGF signaling inhibitor (cediranib) and sham treatments in mouse tumors using DCE-MRI, DW-MRI, and histology. Neoplasia 2012, 14(1):54-64.
13. Thoeny H.C., Ross B.D. Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging 2010, 32(1):2-16.
14. Galban C.J., Chenevert T.L., Meyer C.R., Tsien C., Lawrence T.S., Hamstra D.A., et al. Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment. Clin Cancer Res 2011, 17(14):4751-4760.
15. Sun Y.S., Zhang X.P., Tang L., Ji J.F., Gu J., Cai Y., et al. Locally advanced rectal carcinoma treated with preoperative chemotherapy and radiation therapy: preliminary analysis of diffusion-weighted MR imaging for early detection of tumor histopathologic downstaging. Radiology 2010, 254(1):170-178.
16. Padhani A.R., Liu G., Koh D.M., Chenevert T.L., Thoeny H.C., Takahara T., et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009, 11(2):102-125.
17. Gibbs P., Pickles M.D., Turnbull L.W. Repeatability of echo-planar-based diffusion measurements of the human prostate at 3T. Magn Reson Imaging 2007, 25(10):1423-1429.
18. Kim S.Y., Lee S.S., Park B., Kim N., Kim J.K., Park S.H., et al. Reproducibility of measurement of apparent diffusion coefficients of malignant hepatic tumors: effect of DWI techniques and calculation methods. J Magn Reson Imaging 2012, 36(5):1131-1138.
19. Koh D.M., Blackledge M., Collins D.J., Padhani A.R., Wallace T., Wilton B., et al. Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol 2009, 19(11):2728-2738.
20. O'Flynn E.A., Morgan V.A., Giles S.L., deSouza N.M. Diffusion weighted imaging of the normal breast: reproducibility of apparent diffusion coefficient measurements and variation with menstrual cycle and menopausal status. Eur Radiol 2012, 22(7):1512-1518.
21. Ritter C.A., Perez-Torres M., Rinehart C., Guix M., Dugger T., Engelman J.A., et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007, 13(16):4909-4919.
22. Anderson A.W., Gore J.C. Analysis and correction of motion artifacts in diffusion weighted imaging. Magn Reson Med 1994, 32(3):379-387.
23. Bland J.M., Altman D.G. Measuring agreement in method comparison studies. Stat Methods Med Res 1999, 8(2):135-160.
24. Galbraith S.M., Lodge M.A., Taylor N.J., Rustin G.J., Bentzen S., Stirling J.J., et al. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed 2002, 15(2):132-142.
25. Landis J.R., Koch G.G. The measurement of observer agreement for categorical data. Biometrics 1977, 33(1):159-174.
26. Suh J.Y., Cho G., Song Y., Lee C.K., Kang J.S., Kang M.R., et al. Is apparent diffusion coefficient reliable and accurate for monitoring effects of antiangiogenic treatment in a longitudinal study?. J Magn Reson Imaging 2012, 35(6):1430-1436.
27. Westin C.F., Maier S.E., Mamata H., Nabavi A., Jolesz F.A., Kikinis R. Processing and visualization for diffusion tensor MRI. Med Image Anal 2002, 6(2):93-108.
28. Galban C.J., Maderwald S., Uffmann K., de Greiff A., Ladd M.E. Diffusive sensitivity to muscle architecture: a magnetic resonance diffusion tensor imaging study of the human calf. Eur J Appl Physiol 2004, 93(3):253-262.
29. Williams S.E., Heemskerk A.M., Welch E.B., Li K., Damon B.M., Park J.H. Quantitative effects of inclusion of fat on muscle diffusion tensor MRI measurements. J Magn Reson Imaging 2013, 38(5):1292-1297.
30. Galbraith S.M., Rustin G.J., Lodge M.A., Taylor N.J., Stirling J.J., Jameson M., et al. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 2002, 20(18):3826-3840.